All the big CROs have made a practice of highlighting their full-service expertise in drug development in recent years. They've been styling themselves as consultants capable of guiding companies through not just development, but also the regulatory process and push into the market. And now Quintiles, which has been steadily building up its operations in Asia, wants to do the same for biopharma clients operating in the region.
Building on its work related to 15 projects in China, Quintiles has set up new units for drug development and consulting on Asian projects for clients, aiming at the "commercialization opportunity and regulatory hurdles in advance of the standardized development process."
"Beyond simply helping customers meet their needs in the region, our goals are to help define them," said Amar Kureishi, the CMO and head of strategic drug development for Quintiles in Asia.
Quintiles has been steadily building operations in China. Just a few weeks ago the CRO announced plans to create a business process outsourcing and project management center in Dalian, with plans to eventually recruit 500 staffers for data management, biostatistics, medical writing, pharmacovigilance, post-marketing safety surveillance and back-office support for clients.
In a separate announcement, Quintiles also unveiled plans to work with joint venture partners in the Middle East on outsourced sales support for pharmaceutical marketing.
- read the press release on China
- here's the press release on the Middle East